Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2008
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003594 (A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum), which is not on this map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Pooled it
- Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis.Techniques in coloproctology · 2016Pooled it
- Diabetes mellitus and colorectal cancer prognosis: a meta-analysis.Diseases of the colon and rectum · 2013Pooled it
- Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.Transactions of the American Clinical and Climatological Association · 2010Pooled it
- IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.JNCI cancer spectrum · 2021Trial
- A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer.Cancer medicine · 2014Trial
- Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.American journal of cancer research · 2022Article
- Review
- N-Terminomics Strategies for Protease Substrates Profiling.Molecules (Basel, Switzerland) · 2021Review
- Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.International journal of molecular sciences · 2021Review
- Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study.Cancer research and treatment · 2021Article
- The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer.BioMed research international · 2020Article
- Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study.Cancer medicine · 2018Article
- Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival.Annals of surgical oncology · 2017Article
- Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum.World journal of gastroenterology · 2016Review
- Pre-diagnostic meat and fibre intakes in relation to colorectal cancer survival in the European Prospective Investigation into Cancer and Nutrition.The British journal of nutrition · 2016Article
- Expression array analysis of the hepatocyte growth factor invasive program.Clinical & experimental metastasis · 2015Article
- MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).The Journal of biological chemistry · 2014Article
- Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.World journal of gastroenterology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeInsulin-like growth factor (IGF)-I and IGF-II stimulate neoplastic cell growth and inhibit apoptosis, whereas IGF-binding protein-3 (IGFBP-3) inhibits the bioavailability of IGF-I and has independent proapoptotic activity. We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer. EXPERIMENTAL
designThe plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide as well as data on prognostic factors and body size were measured at baseline among 527 patients participating in a randomized trial of first-line chemotherapy for metastatic colorectal cancer.
resultsHigher baseline plasma IGFBP-3 levels were associated with a significantly greater chemotherapy response rate (P = 0.03) after adjusting for other prognostic factors, whereas neither IGF-I nor IGF-II levels significantly predicted tumor response. Higher levels of IGF-I, IGF-II, and IGFBP-3 were all univariately associated with improved overall survival (P = 0.0001 for all). In a model that mutually adjusted for IGF-I and IGFBP-3, as well as other prognostic factors, increasing baseline-circulating IGFBP-3 was associated with a significantly longer time to tumor progression (P = 0.03), whereas circulating IGF-I was not associated with disease progression (P = 0.95). Levels of C-peptide were not associated with any measure of patient outcome.
conclusionAmong colorectal cancer patients receiving first-line chemotherapy, increasing levels of IGFBP-3, an endogenous antagonist to IGF-I, are associated with an improved objective treatment response and a prolonged time to cancer progression. The IGF pathway may represent an important target for future treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.